Biogen Inc (BIIB)
208.90
+6.44
(+3.18%)
USD |
NASDAQ |
Apr 26, 16:00
209.50
+0.60
(+0.29%)
After-Hours: 20:00
Biogen Revenue (TTM): 9.663B for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.663B |
| December 31, 2023 | 9.836B |
| September 30, 2023 | 9.993B |
| June 30, 2023 | 9.972B |
| March 31, 2023 | 10.10B |
| December 31, 2022 | 10.17B |
| September 30, 2022 | 10.36B |
| June 30, 2022 | 10.63B |
| March 31, 2022 | 10.82B |
| December 31, 2021 | 10.98B |
| September 30, 2021 | 11.10B |
| June 30, 2021 | 11.70B |
| March 31, 2021 | 12.60B |
| December 31, 2020 | 13.44B |
| September 30, 2020 | 14.26B |
| June 30, 2020 | 14.49B |
| March 31, 2020 | 14.42B |
| December 31, 2019 | 14.38B |
| September 30, 2019 | 14.23B |
| June 30, 2019 | 14.07B |
| March 31, 2019 | 13.81B |
| December 31, 2018 | 13.45B |
| September 30, 2018 | 13.23B |
| June 30, 2018 | 12.87B |
| March 31, 2018 | 12.59B |
| Date | Value |
|---|---|
| December 31, 2017 | 12.27B |
| September 30, 2017 | 11.84B |
| June 30, 2017 | 11.72B |
| March 31, 2017 | 11.53B |
| December 31, 2016 | 11.45B |
| September 30, 2016 | 11.42B |
| June 30, 2016 | 11.24B |
| March 31, 2016 | 10.94B |
| December 31, 2015 | 10.76B |
| September 30, 2015 | 10.57B |
| June 30, 2015 | 10.30B |
| March 31, 2015 | 10.13B |
| December 31, 2014 | 9.703B |
| September 30, 2014 | 9.028B |
| June 30, 2014 | 8.345B |
| March 31, 2014 | 7.647B |
| December 31, 2013 | 6.932B |
| September 30, 2013 | 6.384B |
| June 30, 2013 | 5.942B |
| March 31, 2013 | 5.640B |
| December 31, 2012 | 5.516B |
| September 30, 2012 | 6.164B |
| June 30, 2012 | 5.822B |
| March 31, 2012 | 5.610B |
| December 31, 2011 | 5.521B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
9.663B
Minimum
Mar 2024
14.49B
Maximum
Jun 2020
11.86B
Average
11.04B
Median
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 34.12B |
| Bristol-Myers Squibb Co | 45.53B |
| Gilead Sciences Inc | 27.12B |
| AbbVie Inc | 54.32B |
| Sage Therapeutics Inc | 91.06M |